

# Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G8CDE071BDA0EN.html>

Date: April 2021

Pages: 150

Price: US\$ 2,400.00 (Single User License)

ID: G8CDE071BDA0EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights:

Global CFTR Modulators Market Opportunity: > US\$ 20 Billion

Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020)

Global CFTR Modulators Market Growth In 2020: 55%

Global CFTR Modulators Pipeline: >30 Drug

Commercially Available CFTR Modulators: 4 Drugs

Trikafta Market Share 2020: > 50%

“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global CFTR Modulators market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 4 commercially available CFTR Modulators with their, market share and the clinical profile.

The advent of CFTR modulators in the management of cystic fibrosis has greatly

transformed the overall market. Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies are targeted drugs which have been developed by the researchers to correct the malfunctioning protein made by the CFTR gene. Because different mutations cause different defects in the protein, the medications that have been developed so far are effective only in people with specific mutations.

Currently, four CFTR Modulators have been approved for the management of cystic fibrosis. Among them, Trikafta developed by Vertex Pharmaceuticals is the first triple combination therapy available to treat patients who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population. This drug has shown high clinical response and has significantly enhanced the median survival rates in patients.

Trikafta was recently granted approval in late 2019 and within short span of time, the drug has dominated the overall CFTR modulator drug market. As of 2020, the novel drug Trikafta have sales of more than US\$ 3 Billion which is expected to rise at high rates to reach about US\$ 5 Billion by 2026. The high market size of the drug is mainly attributed to the increase in prevalence of the disease and the unmet need of combinational therapy in management of them. Moreover, the high adoption rate of this drug is due to its ability to enhance the median survival rates in patients.

The elexacaftor and tezacaftor contained in TRIKAFTA bind to the CFTR protein and facilitate the cellular processing of F508del-CFTR. The combination helps in increasing the amount of CFTR protein delivered to the cell surface, while ivacaftor aids in the gating of the CFTR protein at the cell surface. The combined effect of the three drugs boosts the amount and function of F508del-CFTR at the cell surface. The targeted nature of drug in the management of cystic fibrosis also aids in boosting the growth of CFTR modulator drugs market.

US is currently dominating the market and is expected to do so for next few years. This is mainly due to the rising Caucasian population in the region which has maximum risk of developing the disease. In addition to this, the high adoption rates of novel therapy as well as rising initiative by government to initiate research and development activities will also drive the future of the market. In addition to this, Europe and Asia are also competing to occupy a considerable position in the market by investing a huge amount in research and development.

As per “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” report findings, it is expected that the drug Trikafta will dominate the

market for next few years which is due to its triple combination which have better ability to tackle the complexity of cystic fibrosis disease. The overall CFTR modulator market will also witness high growth rates and rapid approval of several other modulators which are currently under clinical trials. It is expected that CFTR modulator drugs will emerge as a potential drugs in the management of cystic fibrosis in coming years.

## Contents

### **1. INTRODUCTION TO CFTR MODULATORS**

- 1.1 Overview
- 1.2 Evolution of CFTR Modulators

### **2. CFTR MODULATORS MECHANISM OF ACTION**

### **3. GLOBAL CFTR MODULATOR MARKET OVERVIEW**

- 3.1 Current Market Scenario
- 3.2 Future Market Potential of CFTR Modulators

### **4. US CFTR MODULATOR MARKET OVERVIEW**

- 4.1 Current Market Scenario
- 4.2 Future Market Potential of CFTR Modulators

### **5. ROW CFTR MODULATOR MARKET OVERVIEW**

- 5.1 Current Market Scenario
- 5.2 Future Market Potential of CFTR Modulators

### **6. IVACAFTOR (KALYDECO) - CLINICAL & COMMERCIAL INSIGHT**

- 6.1 Overview
- 6.2 Patents & Assignees
- 6.3 Price & Dosage Insight
- 6.4 Sales Analysis

### **7. IVACAFTOR/LUMACAFTOR (ORKAMBI) - CLINICAL & COMMERCIAL INSIGHT**

- 7.1 Overview
- 7.2 Patents & Assignees
- 7.3 Price & Dosage Insight
- 7.4 Sales Analysis

### **8. TEZACAFTOR/IVACAFTOR (SYMDEKO) - CLINICAL & COMMERCIAL INSIGHT**

- 8.1 Overview
- 8.2 Patent & Assignees
- 8.3 Price & Dosage Insight
- 8.4 Sales

## **9. ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (TRIKAFTA) - CLINICAL & COMMERCIAL INSIGHT**

- 9.1 Overview
- 9.2 Patent & Assignees
- 9.3 Price & Dosage Insight
- 9.4 Global Sales

## **10. GLOBAL CFTR MODULATORS VACCINE PIPELINE OVERVIEW**

- 10.1 By Country
- 10.2 By Company
- 10.3 By Patient Segment
- 10.4 By Phase

## **11. GLOBAL CFTR MODULATORS CLINICAL TRIALS INSIGHT**

- 11.1 Research
- 11.2 Preclinical
- 11.3 Phase-I
- 11.4 Phase-I/II
- 11.5 Phase-II
- 11.6 Phase-III

## **12. MARKETED CFTR MODULATORS CLINICAL INSIGHTS**

## **13. CFTR MODULATOR DRUGS MARKET DYNAMICS**

- 13.1 Favorable Parameters
- 13.2 Market Restraints

## **14. CFTR MODULATOR MARKET FUTURE PERSPECTIVE**

## **15. COMPETITIVE LANDSCAPE**

15.1 Vertex Pharmaceuticals

15.2 Eloxx Pharma

15.3 ReCode Therapeutics

15.4 Arcturus Therapeutics

15.5 AbbVie

15.6 Spirovant Sciences

15.7 Translate Bio

15.8 ReAlta Life Sciences

15.9 Southern Research Institute

15.10 4D Molecular Therapeutics

## List Of Figures

### LIST OF FIGURES

Figure 1-1: Different Approaches for CFTR Modulators

Figure 1-2: Classes of CFTR Protein Mutations

Figure 1-3: History of CFTR Modulators

Figure 2-1: CFTR Modulators – Specific Target for Different Approaches

Figure 3-1: Global – CFTR Modulator Drugs Market Size (US\$ Million), 2017-2020

Figure 3-2: Global – CFTR Modulator Drugs Market Size by Product (US\$ Million), 2019 & 2020

Figure 3-3: Global – CFTR Modulator Drugs Market Size by Product (%), 2020

Figure 3-4: Global – CFTR Modulator Drugs Market Size by Product (%), 2019

Figure 3-5: Global – CFTR Modulator Drugs Market (US\$ Billion), 2021-2026

Figure 3-6: Global – Cystic Fibrosis Incidence, 2020-2026

Figure 4-1: US – Incidence of Cystic Fibrosis, 2010-2020

Figure 4-2: Global – CFTR Modulator Market Size by Region (US\$ Billion), 2020

Figure 4-3: Global – CFTR Modulator Market Size by Region (%), 2020

Figure 4-4: US – Expected CFTR Modulator Drugs Market Size (US\$ Billion), 2021-2026

Figure 4-5: US – Cystic Fibrosis Incidence, 2021-2026

Figure 5-1: Global – CFTR Modulator Market Size by Region (US\$ Billion), 2020

Figure 5-2: Global – CFTR Modulator Market Size by Region (%), 2020

Figure 5-3: ROW – Expected CFTR Modulator Drugs Market Size (US\$ Billion), 2021-2026

Figure 5-4: ROW – Cystic Fibrosis Incidence, 2020-2026

Figure 6-1: US – Kalydeco FDA Approval History

Figure 6-2: Europe – Kalydeco FDA Approval History

Figure 6-3: US- Kalydeco FDA Approval & Patent Expiration Year

Figure 6-4: Europe - Kalydeco FDA Approval & Patent Expiration Year

Figure 6-5: US – Kalydeco Patent Approval & Expiration Year

Figure 6-6: US – Cost of Supply of 56 Oral Granule & Per Unit Cost of Kalydeco Oral Granule (US\$), April'2021

Figure 6-7: US – Cost of Supply of 56 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (US\$), April'2021

Figure 6-8: US – Cost of Supply of 60 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (US\$), April'2021

Figure 6-9: Europe – Cost of Supply of 28 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (Eur/US\$), April'2021

- Figure 6-10: Europe – Cost of Supply of 56 Oral Tablet & Per Unit Cost of 50mg, 75mg & 150mg Kalydeco Oral Tablet (Eur/US\$), April'2021
- Figure 6-11: UK – Cost of Supply of 56 Oral Granules & Per Unit Cost of 25mg, 50mg & 75mg Kalydeco Oral Granules (Eur/US\$), April'2021
- Figure 6-12: UK – Cost of Supply of 56 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (Eur/US\$), April'2021
- Figure 6-13: UK – Cost of Supply of 28 Oral Tablet & Per Unit Cost of 150mg Kalydeco Oral Tablet (Eur/US\$), April'2021
- Figure 6-14: Kalydeco – Recommended Pediatric Dose of Oral Granules for Cystic Fibrosis by Weight (mg/12hrs)
- Figure 6-15: Kalydeco – Maximum Recommended Pediatric Dose for Cystic Fibrosis by Type (mg/12hrs)
- Figure 6-16: Global – Kalydeco Annual Sales (US\$ Million), 2017-2020
- Figure 6-17: Global – Kalydeco Quarterly Sales (US\$ Million), 2020
- Figure 6-18: Global – Kalydeco Quarterly Sales (US\$ Million), 2019
- Figure 7-1: US – Orkambi FDA Approval History by Age
- Figure 7-2: Europe – Orkambi FDA Approval History by Age
- Figure 7-3: US- Orkambi FDA Approval & Patent Expiration Year
- Figure 7-4: Europe - Orkambi FDA Approval & Patent Expiration Year
- Figure 7-5: US – Orkambi Patent Approval & Expiration Year
- Figure 7-6: US - Cost of Supply of 56 Oral Granule & Per Unit Cost of Orkambi Oral Granule (US\$), April'2021
- Figure 7-7: US - Cost of Supply of 112 Oral Tablet & Per Unit Cost of Orkambi Oral Tablet (US\$), April'2021
- Figure 7-8: Europe - Cost of Supply of 112 Oral Tablet & Per Unit Cost of Orkambi Oral Tablet (Euro/US\$), April'2021
- Figure 7-9: UK- Cost of Supply of 112 Oral Tablet & Per Unit Cost of Orkambi Oral Tablet (Euro/US\$), April'2021
- Figure 7-10: UK- Cost of Supply of 56 Oral Granules & Per Unit Cost of Orkambi Oral Granule (Euro/US\$), April'2021
- Figure 7-11: Orkambi - Recommended Dose by Age (mg/day)
- Figure 7-12: Global - Orkambi Annual Sales (US\$ Million), 2017-2020
- Figure 7-13: Global - Orkambi Quarterly Sales (US\$ Million), 2020
- Figure 7-14: Global - Orkambi Quarterly Sales (US\$ Million), 2019
- Figure 8-1: US - Symdeko FDA Approval History by Age
- Figure 8-2: Europe - Symdevi EU Approval History by Age
- Figure 8-3: Europe - Symdevi Approval & Patent Expiration Year
- Figure 8-4: US - Symdeko Approval & Patent Expiration Year
- Figure 8-5: US - Symdeko Patent Approval & Expiration Year



Figure 8-6: US - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Symdeko Oral Tablet (US\$), April'2021

Figure 8-7: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Symdeko Oral Tablet (Euro/US\$), April'2021

Figure 8-8: Europe - Cost of Supply of 28 Oral Tablet & Per Unit Cost of Symkevi Oral Tablet (Euro/US\$), April'2021

Figure 8-9: Global - Symdeko/Symkevi Annual Sales (US\$ Million), 2018-2020

Figure 8-10: Global - Symdeko/Symkevi Quarterly Sales (US\$ Million), 2020

Figure 8-11: Global - Symdeko/Symkevi Quarterly Sales (US\$ Million), 2019

Figure 9-1: US - Trikafta FDA Approval History by Mutation

Figure 9-2: Trikafta/Kaftrio - Initial Approval Year by Region

Figure 9-3: Europe - Kaftrio Approval & Patent Expiration Year

Figure 9-4: US - Trikafta Approval & Patent Expiration Year

Figure 9-5: US - Trikafta Patent Approval & Expiration Year

Figure 9-6: US - Cost of Supply of 84 Oral Tablet & Per Unit Cost of Trikafta Oral Tablet (US\$), April'2021

Figure 9-7: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US\$), April'2021

Figure 9-8: UK - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US\$), April'2021

Figure 9-9: Trikafta/Kaftrio - Recommended Initial & Reduced Dose (mg/day)

Figure 9-10: Global - Trikafta/Kaftrio Annual Sales (US\$ Million), 2019 & 2020

Figure 9-11: Global - Trikafta/Kaftrio Quarterly Sales (US\$ Million), 2020

Figure 10-1: Global - CFTR Modulators in Clinical Pipeline by Country, 2021 till 2026

Figure 10-2: Global - CFTR Modulators in Clinical Pipeline by Company, 2021 till 2026

Figure 10-3: Global – CFTR Modulators in Clinical Pipeline by Patient Segment, 2021 till 2026

Figure 10-4: Global - CFTR Modulators in Clinical Pipeline by Phase, 2021 till 2026

Figure 13-1: CFTR Modulator Market Favorable Parameters

Figure 13-2: Global - CFTR Modulator Annual Sales by Product (US\$ Million), 2020

Figure 13-3: US - CFTR Modulator Annual WAC by Product (US\$)

Figure 13-4: Stages of Drug Development

## I would like to order

Product name: Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G8CDE071BDA0EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8CDE071BDA0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970